CAR-T cell therapy for treatment-resistant inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat inflammatory bowel disease (IBD) that has not responded to standard treatments. The therapy is engineered to target specific immune cells involved in IBD inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 and weigh at least 40 kg
- Diagnosed with IBD for at least 3 months with moderate-to-severe active disease confirmed by endoscopy
- Failed or couldn't tolerate at least one advanced IBD treatment (biologics or immunosuppressants)
- No prior CAR-T cell therapy or BCMA/CD19-targeted cell therapies
- No active infections (hepatitis B/C, HIV, TB), cancer, or severe organ damage
- Able to participate in leukapheresis (blood cell collection procedure) and colonoscopy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
This trial tests a new type of immune cell therapy called CAR-T cells, which target two proteins (CD19 and BCMA) to reduce inflammation in the gut. It is designed for adults with moderate to severe ulcerative colitis or Crohn's disease that has not responded well to other treatments.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Hear when a new Inflammatory Bowel Diseases (IBD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.